FRIDAY, Feb. 21, 2025 — For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax with or without obinutuzumab significantly prolongs progression-free survival compared with…Original Article
Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia
FRIDAY, Feb. 21, 2025 — For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax with or without obinutuzumab significantly prolongs progression-free survival compared with…
